Therapeutic activity of enviroxime against rhinovirus infection in volunteers
Open Access
- 1 May 1983
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 23 (5), 671-675
- https://doi.org/10.1128/aac.23.5.671
Abstract
The therapeutic effect of intranasal 2-amino-1-(isopropylsulphonyl)-6-benzimidazole phenyl ketone oxime (enviroxime) against human rhinovirus type 9 was evaluated in a double-blind, placebo-controlled volunteer trial. Enviroxime given 6 times a day was well tolerated, producing a reduction in clinical evidence of infection which coincided with the start of medication (44 h after virus challenge). Although there was a statistically significant reduction in clinical score in the enviroxime group on day 5 after virus challenge, reductions in total clinical score accumulated during the trial and reductions in the quantity of nasal secretions were not significant. A separate analysis was performed on data from volunteers who did not have symptoms when medication began (and who might have been expected to benefit more from enviroxime therapy). No apparent enhancement of the effects of enviroxime could be demonstrated in this group.This publication has 4 references indexed in Scilit:
- Failure of oral 4′, 6-dichloroflavan to protect against rhinovirus infection in manArchiv für die gesamte Virusforschung, 1983
- THE ACTIVITY OF ENVIROXIME AGAINST RHINOVIRUS INFECTION IN MANThe Lancet, 1981
- Inhibition of Rhinovirus Replication in Organ Culture by a Potential Antiviral DrugThe Journal of Infectious Diseases, 1980
- Distribution and removal of human serum albumin-technetium 99m instilled intranasally.British Journal of Clinical Pharmacology, 1976